You may not know it, but this year marks a milestone in the world of SSRI teratology research. Ten years ago, JAMA published the first controlled study of Prozac exposure in pregnancy (1). The results? Neither Prozac nor tricyclics caused more birth defects than controls, but both antidepressants caused more neonatal complications.

It’s not all about meds. This is especially true in treating postpartum depression, because so many women are understandably reluctant to expose their breast-feeding infants to antidepressants. This article reviews interpersonal therapy (IPT) as an effective modality for post-partum depression.

There are now no fewer than 14 FDA-approved psychostimulants… and counting. This does not include the many generics, the new non-stimulant Straterra or the off-label ADHD meds Wellbutrin (bupropion) and desipramine.

The Eli Lilly reps are almost delirious about their new ADHD “miracle drug”, Straterra (atomoxetine). This is not surprising.

They have been flooding into your office: grown-ups who believe that they have ADHD.

Panic disorder is a much harder nut to crack than we give it credit for. We tend to get complacent about treating it, because so many patient appear to do well on the standard starting regimen of an SSRI with or without a benzodiazepine.

When it comes to cognitive behavior therapy (CBT) and most psychiatrists, a little knowledge is a troubling thing. We know that CBT is effective, but we don’t know how to practice it. We know that a lot of patients ask us about it, but we don’t know enough to confidently describe to them what it entails.

Neurontin (gabapentin) spends plenty of time in our patient’s medicine cabinets, but lately it has spent nearly as much time splashed across news sections of daily papers. Parke-Davis, the company that used to market Neurontin before it merged with Pfizer, has been accused of improperly promoting its use for a variety of off-label indications (1).

Zyprexa (olanzapine) became rapidly popular after its introduction in the United States in 1996. Its structural similarity to Clozaril (clozapine) led to hopes that it would be as effective for treatment-resistant cases as Clozaril but without the risk of agranulocytosis.

Abilify (aripiprazole) is out! But you probably already know this, if your mailbox and fax machine have become as saturated with BMS-funded missives from CME, Inc. as mine have been. The hired guns are out in force once again, and so we front-line clinicians are faced with the task of separating the authentic wheat from the hyped-up chaff.